Poor diagnostic value of isocitrate dehydrogenase 1 R132H immunohistochemistry for determination of isocitrate dehydrogenase 1 status in patients with glioblastoma
IDH1 status evaluation is crucial to predicting the survival rate and important for guiding the treatment decision for patients with glioblastoma. Despite the lesser sensitivity and specificity of IHC in comparison to DNA sequencing in this study, larger prospective studies are needed to validate our preliminary finding.
Authors
- Edward Jaya Hadi (ORCID: https://orcid.org/0000-0003-0613-8054)
- Ahmad Faried (ORCID: https://orcid.org/0000-0003-2967-8125)
- Hasrayati Agustina (ORCID: https://orcid.org/0000-0001-8817-6753)
Institutions
- Padjadjaran University (ID)
Publication Details
- Journal
- Surgical Neurology International
- Published
- 2025-04-18
- DOI
- https://doi.org/10.25259/sni_881_2024
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00